Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT06735118
Recruiting Not applicable

Feasibility Study of Deep Learning-based MDixon Quant for Quantitative Assessment of Chemotherapy-induced Fatty Liver

NCT06735118 · tracked via the Priya Life Science China tracker
Sponsor
Yunnan Cancer Hospital
Phase
Not applicable
Started
2023-12-25
Last updated
2024-12-16

Condition(s) studied

Non-Alcoholic Fatty Liver Disease

Investigational drug(s) / intervention(s)

Neoadjuvant chemotherapy

Neoadjuvant chemotherapy: Neoadjuvant chemotherapy

Study summary

The purpose of this study is to quantitatively assess the changes in liver fat content in cancer patients before and after treatment.

The main questions it aims to answer are:How does the liver fat fraction change before and after chemotherapy? In this study, patients undergoing mDixon Quant scanning are subjected to fully automated segmentation and measurement of liver fat content using artificial intelligence.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
Accepted
Inclusion Criteria: 1. CT/B ultrasound showed no fatty liver 2. No MRI contraindications, including pacemaker, stent, metal implant, or claustrophobia 3. Received neoadjuvant/adjuvant chemotherapy Exclusion Criteria: 1. Missing follow-up information 2. Liver lesions (metastases, hemangioma, etc.) 3. Poor image quality

Primary outcome measure(s)

  • Extract the whole liver fat fraction — one year
    Extract the whole liver fat fraction using the threshold extraction method.

Trial sites (1)

FacilityCityRegionStatus
Yunnan Cancer Hospital Kunming Yunnan Recruiting

More Yunnan Cancer Hospital trials in China

The Application Value of Spectral CT in the Accurate Staging of Colorectal Cancer Starting soon
Adapalene Gel for Acute Radiation-Induced Skin Injury Recruiting
Study on the Value of Three DWI Scanning Sequences in Staging of Gastric Cancer Recruiting
Tumor-Targeted-NIR-II Fluorescent Molecular Probes for the Identification of Breast Cancer Tissue and SLN Metastatic Status Recruiting
Performance of Diffusion-weighted Imaging-based Virtual MR Elastography (vMRE) for Diagnosing Breast Cancer Active, not recruiting

Other trials for the same condition

A Randomized, Double-blind, Single-center Phase I/IIa Study of XTYW007 Tablets in Subjects. Starting soon
The Effects of Tai Chi on Metabolic Dysfunction-associated Fatty Liver Disease in Middle-Aged and Older Adults Recruiting
BeijngFH Health Cohort Study Recruiting
Risk Factors for Hepatic Inflammation, Fibrosis and Prognosis in Patients With CHB and NAFLD Recruiting
Mechanisms of Macrophage Polarization in HIRI in Patients With NAFLD Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06735118 on ClinicalTrials.gov ↗ ← All trials in China